24 results about "Articular disease" patented technology

The invention belongs to the technical field of pet bone joint prevention and treatment, and particularly provides a stem cell exosome and application thereof in preparation of medicine for preventing and treating pet bone joint diseases. The RANKL monoclonal antibody 5F16 and the mesenchymal stem cell exosome are combined for the first time to be used for preventing and treating the bone joint diseases of the pets, and test analysis shows that the preparation can effectively reduce the levels of IL-1beta, TNF-alpha and IL-6 in serum of the pets caused by bone joint injuries, inhibit secretion of the IL-1beta, the TNF-alpha and the IL-6, repair the bone joint injuries, improve and promote cartilage tissue repair, prevent and treat the bone joint diseases of the pets and prevent and treat the bone joint diseases of the pets. Good application prospects are realized.

The present invention relates to a stem cell therapeutic agent for preventing or treating temporomandibular joint diseases, and a production method therefor. Specifically, stem cells overexpressing at least one gene selected from the group consisting of IDO, TSG -6, and FGF2 are included as an active ingredient. When used, the agent can prevent cartilage loss in the temporomandibular joint and promote bone regeneration, and thus can be advantageously used for the fundamental prevention and treatment of temporomandibular arthritis.

The purpose of the present invention is to provide a disease onset risk prediction device for predicting the risk of onset of a skeletal disease or joint disease from disease-related information of a prediction target individual.　The disease onset risk prediction device according to the present disclosure comprises an information acquisition unit, a prediction unit, and an output unit, wherein: the information acquisition unit acquires disease-related information of a prediction target individual; the disease is a skeletal disease or a joint disease; the disease-related information includes at least one of information acquired through a medical checkup and information acquired by the prediction target individual; the prediction unit predicts the risk of onset of the disease in the prediction target individual from the disease-related information; and the output unit outputs the disease onset risk.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The invention relates to the field of traditional Chinese medicine external preparations, in particular to traditional Chinese medicine external liniment medicinal liquor for dispelling wind, eliminating dampness, activating blood and diminishing swelling, which comprises the following components in parts by weight: 5-15 parts of rheum officinale, 3-10 parts of arisaema consanguineum schott, 8-20 parts of mangnolia officinalis, 6-18 parts of liquorice, 5-12 parts of lotus powder, 10-25 parts of turmeric, 8-20 parts of golden cypress, 6-15 parts of pericarpium citri reticulatae, 5-12 parts of safflower, 8-18 parts of ligusticum wallichii, 10-25 parts of teasel root, 15-30 parts of eucommia ulmoides and 12-28 parts of rhizoma drynariae. The medicinal liquor is prepared from the following raw materials in parts by weight: 3-9 parts of dragon's blood, 8-20 parts of myrrh, 2-6 parts of pearl powder, 5-15 parts of mung bean seed-coat, 1-4 parts of borneol and 200-500 parts of Baijiu. Based on the innovative concept of eliminating evil, strengthening body resistance and multi-target cooperation, four functional components of expelling wind-damp, promoting blood circulation to remove blood stasis, strengthening tendons and bones and promoting tissue regeneration to heal sores are integrated, the limitation of traditional medicinal liquor is broken through through toxic effect balance compatibility and a gradient permeation process, and the externally applied medicinal liquor can improve local blood circulation, relieve inflammation pain and improve the curative effect of the traditional medicinal liquor. In addition, bone metabolism balance can be adjusted, tissue repair is promoted, and a novel treatment choice is provided for patients with chronic osteoarticular diseases and compound trauma.

The invention provides immortalized adipose-derived mesenchymal stem cells as well as a preparation method and application thereof, and belongs to the technical field of cells, the preparation method comprises the following steps: separating adipose tissues, constructing cells to be screened by the obtained adipose-derived mesenchymal stem cells, and screening to obtain the immortalized adipose-derived mesenchymal stem cells; the immortalized adipose-derived mesenchymal stem cells are used for treating neurological diseases, respiratory system diseases, cardiovascular diseases, osteoarticular diseases, urinary system diseases, digestive system diseases, skin diseases or autoimmune diseases. According to the invention, by preparing the immortalized canine adipose-derived mesenchymal stem cells and utilizing an intranasal administration mode, the nervous system degenerative diseases can be safely and effectively relieved.

The present invention provides an external brace, an orthosis, for treating disorders of joints in dogs and cats. The most relevant veterinary indication is a hock joint brace to treat cranial cruciate disease in dogs.

A microgel composition comprising micron-sized particles of poly(acrylic acid) in which at least a portion of carboxylic acid groups in the poly(acrylic acid) are crosslinked as shown in the following structure: wherein: L is a linear or branched polyalkylene glycol-containing linker, or L more particularly has the following formula: —O—[CH(R)CH(R′)—O]x—; R and R′ are independently selected from H and CH3; and x is an integer of 1-50; wherein the micron-sized particles have an average diameter of at least 1 micron. Methods for imparting lubricity to a biological tissue and methods for treating an articular disease or condition (e.g., arthritis or osteoarthritis) by administering the microgel composition are also described.

The present disclosure relates generally to joint health supplement compositions derived from a xenogeneic cartilaginous tissue source, methods of making such compositions, as well as methods of using such compositions, for example, to treat joint pain or other joint ailments due to arthritis in human and animal populations both at risk and actively presenting with such joint pain or other joint ailments. One aspect of the present disclosure can include a nutritional joint health supplement composition including a cartilaginous tissue material harvested from a xenogeneic tissue source and at least a trace amount of a detergent, wherein the nutritional joint health supplement composition has a beneficial component profile and reduced cellular and DNA content.

The invention discloses a traditional Chinese medicine composition for treating joint diseases and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 25 to 45 parts of radix angelicae pubescentis, 25 to 45 parts of cortex phellodendri, 20 to 40 parts of rhizoma smilacis glabrae, 20 to 40 parts of rhizoma dioscoreae septemlobae, 20 to 40 parts of rhizoma chuanxiong, 20 to 40 parts of semen coicis, 20 to 40 parts of radix cyathulae, 20 to 40 parts of herba artemisiae scopariae, 20 to 40 parts of herba lycopodii, 20 to 40 parts of rhizoma polygoni cuspidati, 20 to 40 parts of radix dipsaci, 20 to 40 parts of rhizoma atractylodis, 20 to 40 parts of semen plantaginis and 10 to 25 parts of liquorice root. The traditional Chinese medicine composition has a relatively good treatment effect on gout, rheumatic arthritis and rheumatoid arthritis, can treat both symptoms and root causes, and is relatively small in side effect and relatively small in harm to a human body.

The invention belongs to the technical field of traditional Chinese medicine compositions, and provides a traditional Chinese medicine composition for treating osteoarticular diseases. The traditional Chinese medicine composition for treating osteoarticular diseases is prepared from the following raw materials in parts by weight: 35 to 45 parts of short-pedicel aconite root, 25 to 35 parts of radix aconiti preparata, 90 to 100 parts of rhizoma zingiberis, 20 to 30 parts of herba epimedii, 3 to 6 parts of catechu, 9 to 14 parts of caulis spatholobi, 2 to 5 parts of rhizoma corydalis, 1 to 3 parts of liquorice root and 1 to 3 parts of borneol. Compared with ostalgia tincture, the traditional Chinese medicine composition not only can regulate bone metabolism, tonify kidney and strengthen bone and treat liver and kidney deficiency essence of hyperosteogeny, has the effects of reducing toxicity and enhancing efficacy, but also can reduce irritation to skin and greatly reduce use side effects.

Provided herein are joint deliverable oligonucleotide modulators and the use thereof in the treatment of joint diseases, such as rheumatoid arthritis (RA). The intra-articular (IA) deliverable oligonucleotide agents comprise: a double-stranded oligonucleotide capable of modulating the expression of a selected gene associated to a joint disease, and one or more delivery moieties conjugating to the double-stranded oligonucleotide for delivery of the oligonucleotide to cells in the joint. Also provided are products comprising the same, methods for delivering the same to cells in the joint, and methods for the treatment of joint diseases using the same.

The present disclosure is directed to peptide-polymer conjugates, and to their use in treating intra-articular diseases or disorders.

Compositions and methods of treatment are disclosed using compositions of extracts from the fruit of the Synsepalum dulcificum tree, which when applied topically in mammals, can provide benefit for dermatological and joint conditions. The extracts also contain anti-inflammatory, antimicrobial and spermicidal activity in vitro.

The present disclosure relates to a compound selected from the group consisting of pterostilbene or a cocrystal thereof; silybin or a pharmaceutically acceptable salt of thereof, or any stereoisomer or mixtures of stereoisomers of any of them; a complex of silybin or of any of stereoisomer or mixtures of stereoisomers thereof; or a glycoside of silybin or of any stereoisomer or mixtures of stereoisomers thereof, either for use in the treatment of a disease or disorder mediated by the loss of endogenous type I collagen, or for use in joint functionality improvement, articular disease healing; tendon-bone, bone, and muscle repair improvement; or in wound healing. It also relates to combinations of pterostilbene or a cocrystal thereof, and silybin, particularly addressed to the treatment of a disease or disorder mediated by the loss of endogenous type I collagen, as well as to pharmaceutical compositions and kits containing them, and to the use of the latter in for any one of the mentioned treatments.

The present invention relates to a stem cell spheroid therapeutic agent for preventing or treating a temporomandibular joint disease and a method for producing same. Specifically, the stem cell spheroid therapeutic agent comprises, as an active ingredient, stem cell spheroids overexpressing at least one gene selected from the group consisting of IDO and FGF2, and when used, prevents cartilage loss in temporomandibular joints and promotes bone regeneration, and has an anti-inflammatory effect, and thus can be effectively used for the fundamental prevention and treatment of temporomandibular arthritis.

Water-soluble hydroxybisphosphonic derivatives of meloxicam may be used as a drug, especially for the treatment of inflammatory joint diseases. Pharmaceutical compositions include such water-soluble hydroxybisphosphonic derivatives of meloxicam and at least one excipient. Methods are used to synthesize such hydroxybisphosphonic derivatives of meloxicam.

The present invention relates to new hyaluronic acid binding proteins. The invention refers to new engineered fusion proteins for use in treating disorders of the eye or the joints. The fusion proteins comprise a subunit that specifically binds to hyaluronic acid. In addition to the hyaluronic acid binding protein, the new fusion proteins comprise a protein therapeutically effective in diseases of the eye or of joints. The fusion proteins are particularly well-suited for medical applications that require extended half-life of eye specific therapeutic proteins.

The present invention relates to pharmaceutical compositions comprising mixtures of a statin and a hyaluronic acid amide derivative which are useful in the treatment of inflammation and degradation of osteoarthritic joint cartilage, in particular post-traumatic osteoarthrosis and osteoarthrosis caused by physiological joint aging, and in the treatment of other joint disorders such as rheumatoid arthritis.

The present invention provides a second use of mitochondria, which can cure a tendon injury-related disease and prevent a disease caused by a tendon injury. Specifically, the mitochondria disclosed in the present invention have the effect of repairing injured tendon cells and accelerating the healing of the tendon cells. Therefore, by administering a predetermined amount of mitochondria or a composition containing a predetermined amount of mitochondria to a part with a tendon injury, wound healing of the part with the tendon injury can be promoted, thus achieving the effect of repairing the injured tendon and further preventing a joint disease caused by the tendon injury or inflammation.

The invention relates to the field of plasters, in particular to a plaster for treating bone fractures and joint diseases and a preparation method thereof.The plaster for treating bone fractures and joint diseases is formed by sequentially overlapping spunlace non-woven fabric, an ointment layer and release paper from top to bottom; the ointment layer is prepared from the following raw materials: cinnamon, pine nodular branch, sappan wood, sambucus chinensis, teasel root, radix angelicae, rhizoma drynariae, notopterygium root, radix angelicae pubescentis, divaricate saposhnikovia root, angelica sinensis, ligusticum wallichii, pseudo-ginseng, dragon's blood, 40-60 parts of native copper, frankincense, myrrh, eucommia ulmoides, ephedra, radix achyranthis bidentatae, peach kernel, safflower, stiff silkworm, scorpion, centipede, radix clematidis, kochia scoparia, hedyotis diffusa, sambucus williamsii, pimpinella tuberosa, sarcodactylis, piper wallichii, vaccinium bracteatum, zaocys dhumnade and pressure-sensitive adhesive. The plaster for treating bone fracture and joint diseases has the advantages of being good in treatment effect, small in side effect, good in environmental protection property and free of residues.

The invention belongs to the technical field of biomedical materials, and particularly relates to a MoS2 and Bi2S3 belonging to HA biological piezoelectric material as well as a preparation method and application of the MoS2 and Bi2S3 belonging to HA biological piezoelectric material. The preparation method comprises the following steps: growing a MoS2 thin layer on the surface of a Bi2S3 nanorod to prepare MoS2 and Bi2S3; the preparation method comprises the following steps: dispersing MoS2 at Bi2S3 into a hyaluronic acid solution to obtain MoS2 at Bi2S3 belonging to HA; the material has the following characteristics: (1) the activity of catalase-like and glutathione-like reductase is obviously enhanced under the ultrasonic action, and active oxygen is efficiently removed; hydrogen and electrical stimulation are generated in the inflammatory microenvironment through the piezoelectric effect, expression of inflammatory factors is inhibited, and cartilage repair is promoted. The preparation process of the material is simplified, the material is suitable for treating inflammatory joint diseases such as arthritis and synovitis, and targeted therapy can be achieved through local injection or articular cavity drug delivery.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR / Cas9 gene editing system.

The invention belongs to the technical field of medicines, particularly relates to application of eupatilin in treatment of synovial arthropathy (such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and the like) and other joint diseases characterized by synovial pathology hyperplasia, and provides novel application of eupatilin in preparation of medicines for resisting synovial arthropathy. Particularly, the compound has a good inhibition effect on abnormal behaviors such as proliferation and invasion of synovial fibroblasts; eupatilin is provided as an effective medicine component for treating joint deformation, and the main action mechanism is that clinical symptoms are relieved by inhibiting proliferation and invasion of RA-FLS; the innovation of the invention lies in providing a therapy based on eupatilin, and through application of a specific dosage, joint inflammation of patients can be effectively relieved and joint functions can be improved.